CA2620274C - Methods for the treatment of senile dementia of the alzheimer's type - Google Patents
Methods for the treatment of senile dementia of the alzheimer's type Download PDFInfo
- Publication number
- CA2620274C CA2620274C CA2620274A CA2620274A CA2620274C CA 2620274 C CA2620274 C CA 2620274C CA 2620274 A CA2620274 A CA 2620274A CA 2620274 A CA2620274 A CA 2620274A CA 2620274 C CA2620274 C CA 2620274C
- Authority
- CA
- Canada
- Prior art keywords
- sdat
- alkyl
- acyl
- glycerol
- dha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 59
- 238000011282 treatment Methods 0.000 title claims abstract description 36
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title description 68
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims abstract description 75
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims abstract description 19
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 150000001982 diacylglycerols Chemical class 0.000 claims abstract description 6
- 230000003247 decreasing effect Effects 0.000 claims description 51
- 238000012360 testing method Methods 0.000 claims description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 27
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 21
- 230000002265 prevention Effects 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- 230000001149 cognitive effect Effects 0.000 claims description 11
- 150000004665 fatty acids Chemical class 0.000 claims description 11
- 210000002824 peroxisome Anatomy 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 238000004949 mass spectrometry Methods 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 3
- 230000003557 neuropsychological effect Effects 0.000 claims description 3
- 229940055577 oleyl alcohol Drugs 0.000 claims description 3
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 230000003028 elevating effect Effects 0.000 claims 11
- 229940124597 therapeutic agent Drugs 0.000 claims 11
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 150000004671 saturated fatty acids Chemical class 0.000 claims 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 1
- -1 ethanolamine phospholipids Chemical class 0.000 abstract description 36
- 206010012289 Dementia Diseases 0.000 description 156
- 239000002207 metabolite Substances 0.000 description 75
- 210000002966 serum Anatomy 0.000 description 71
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 70
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 45
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 37
- 235000012000 cholesterol Nutrition 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 239000000523 sample Substances 0.000 description 30
- 238000004885 tandem mass spectrometry Methods 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 29
- 230000000694 effects Effects 0.000 description 29
- 230000007170 pathology Effects 0.000 description 28
- 230000007423 decrease Effects 0.000 description 27
- 208000010877 cognitive disease Diseases 0.000 description 26
- 239000012528 membrane Substances 0.000 description 23
- 230000000858 peroxisomal effect Effects 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- 210000004556 brain Anatomy 0.000 description 22
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 21
- 150000002500 ions Chemical class 0.000 description 21
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 21
- 238000009825 accumulation Methods 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 20
- 230000002503 metabolic effect Effects 0.000 description 20
- 210000004885 white matter Anatomy 0.000 description 19
- 238000003556 assay Methods 0.000 description 18
- 239000002243 precursor Substances 0.000 description 18
- 238000001228 spectrum Methods 0.000 description 18
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 17
- 235000005911 diet Nutrition 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 17
- 241000282412 Homo Species 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 238000009826 distribution Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000003169 central nervous system Anatomy 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 14
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 14
- 208000028698 Cognitive impairment Diseases 0.000 description 14
- 238000003745 diagnosis Methods 0.000 description 14
- 230000000378 dietary effect Effects 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 13
- 230000002950 deficient Effects 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 210000004884 grey matter Anatomy 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 230000032683 aging Effects 0.000 description 12
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 101150041968 CDC13 gene Proteins 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 230000004064 dysfunction Effects 0.000 description 10
- 230000036542 oxidative stress Effects 0.000 description 10
- 150000003904 phospholipids Chemical class 0.000 description 10
- 230000009469 supplementation Effects 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 208000027061 mild cognitive impairment Diseases 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 230000001713 cholinergic effect Effects 0.000 description 8
- 230000004770 neurodegeneration Effects 0.000 description 8
- 230000002981 neuropathic effect Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 7
- 201000011240 Frontotemporal dementia Diseases 0.000 description 7
- 201000002832 Lewy body dementia Diseases 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 206010072731 White matter lesion Diseases 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 210000002932 cholinergic neuron Anatomy 0.000 description 7
- 230000001054 cortical effect Effects 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 230000006735 deficit Effects 0.000 description 7
- 238000003748 differential diagnosis Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- 238000002600 positron emission tomography Methods 0.000 description 7
- 210000004129 prosencephalon Anatomy 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 230000006641 stabilisation Effects 0.000 description 7
- 238000011105 stabilization Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 6
- 230000008238 biochemical pathway Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 230000001590 oxidative effect Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 5
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 5
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 5
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 208000012902 Nervous system disease Diseases 0.000 description 5
- 208000025966 Neurological disease Diseases 0.000 description 5
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 5
- 230000037444 atrophy Effects 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 230000007850 degeneration Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 210000001320 hippocampus Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 235000020778 linoleic acid Nutrition 0.000 description 5
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 238000003325 tomography Methods 0.000 description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- 102000016938 Catalase Human genes 0.000 description 4
- 108010053835 Catalase Proteins 0.000 description 4
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001044152 Neoclanis basalis Species 0.000 description 4
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- 208000037273 Pathologic Processes Diseases 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000003124 biologic agent Substances 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 238000001815 biotherapy Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000013043 chemical agent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000019771 cognition Effects 0.000 description 4
- 230000001010 compromised effect Effects 0.000 description 4
- 208000017004 dementia pugilistica Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000009054 pathological process Effects 0.000 description 4
- 238000000899 pressurised-fluid extraction Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 201000004810 Vascular dementia Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000000132 electrospray ionisation Methods 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004401 flow injection analysis Methods 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000005040 ion trap Methods 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000000478 neocortex Anatomy 0.000 description 3
- 230000007171 neuropathology Effects 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 102100040679 Dihydroxyacetone phosphate acyltransferase Human genes 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010070246 Executive dysfunction Diseases 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 2
- 101000941356 Nostoc ellipsosporum Cyanovirin-N Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003941 amyloidogenesis Effects 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 229940062310 avandia Drugs 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 238000001360 collision-induced dissociation Methods 0.000 description 2
- 210000000877 corpus callosum Anatomy 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000000537 electroencephalography Methods 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000002582 magnetoencephalography Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000000874 microwave-assisted extraction Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 230000001722 neurochemical effect Effects 0.000 description 2
- 230000017511 neuron migration Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108091006084 receptor activators Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012502 risk assessment Methods 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- WLWNRAWQDZRXMB-YLFCFFPRSA-N (2r,3r,4r,5s)-n,3,4,5-tetrahydroxy-1-(4-phenoxyphenyl)sulfonylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 WLWNRAWQDZRXMB-YLFCFFPRSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 241000543381 Cliftonia monophylla Species 0.000 description 1
- 208000018652 Closed Head injury Diseases 0.000 description 1
- 101710140473 Dihydroxyacetone phosphate acyltransferase Proteins 0.000 description 1
- 101000801260 Homo sapiens Troponin C, slow skeletal and cardiac muscles Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- SSURCGGGQUWIHH-UHFFFAOYSA-N NNON Chemical compound NNON SSURCGGGQUWIHH-UHFFFAOYSA-N 0.000 description 1
- 241001606091 Neophasia menapia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- KUGRPPRAQNPSQD-UHFFFAOYSA-N OOOOO Chemical compound OOOOO KUGRPPRAQNPSQD-UHFFFAOYSA-N 0.000 description 1
- DTAFLBZLAZYRDX-UHFFFAOYSA-N OOOOOO Chemical compound OOOOOO DTAFLBZLAZYRDX-UHFFFAOYSA-N 0.000 description 1
- JLNTWVDSQRNWFU-UHFFFAOYSA-N OOOOOOO Chemical compound OOOOOOO JLNTWVDSQRNWFU-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108010085186 Peroxisomal Targeting Signals Proteins 0.000 description 1
- 208000020547 Peroxisomal disease Diseases 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108091006774 SLC18A3 Proteins 0.000 description 1
- 240000002407 Solanum quitoense Species 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100033744 Troponin C, slow skeletal and cardiac muscles Human genes 0.000 description 1
- 102000045965 Vesicular Acetylcholine Transport Proteins Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000005257 alkyl acyl group Chemical group 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- VZDYWEUILIUIDF-UHFFFAOYSA-J cerium(4+);disulfate Chemical compound [Ce+4].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O VZDYWEUILIUIDF-UHFFFAOYSA-J 0.000 description 1
- 229910000355 cerium(IV) sulfate Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 231100000876 cognitive deterioration Toxicity 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 238000002598 diffusion tensor imaging Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- DXAPNHFOXAMIIR-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoyl chloride Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(Cl)=O DXAPNHFOXAMIIR-UHFFFAOYSA-N 0.000 description 1
- MBMBGCFOFBJSGT-UHFFFAOYSA-N docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CCC=CCC=CCC=CCC=CCC=CCC=CCCC(O)=O MBMBGCFOFBJSGT-UHFFFAOYSA-N 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001073 episodic memory Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- AYAYHFUDSSAHOG-PBHICJAKSA-N ethyl (4as,10bs)-3-methyl-1,2,4,4a,5,6-hexahydrobenzo[f]isoquinoline-10b-carboxylate Chemical compound C1CC2=CC=CC=C2[C@@]2(C(=O)OCC)[C@H]1CN(C)CC2 AYAYHFUDSSAHOG-PBHICJAKSA-N 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 108010075981 glycerone-phosphate O-acyltransferase Proteins 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930182851 human metabolite Natural products 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000001423 neocortical effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000011903 nutritional therapy Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2695167A CA2695167C (en) | 2007-02-08 | 2007-08-27 | Methods for the treatment of elevated cholesterol levels |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88888307P | 2007-02-08 | 2007-02-08 | |
| US60/888,883 | 2007-02-08 | ||
| PCT/CA2007/001472 WO2008095275A1 (en) | 2007-02-08 | 2007-08-27 | Methods for the treatment of senile dementia of the alzheimer's type |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2695167A Division CA2695167C (en) | 2007-02-08 | 2007-08-27 | Methods for the treatment of elevated cholesterol levels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2620274A1 CA2620274A1 (en) | 2008-06-20 |
| CA2620274C true CA2620274C (en) | 2011-10-04 |
Family
ID=39537686
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2695167A Active CA2695167C (en) | 2007-02-08 | 2007-08-27 | Methods for the treatment of elevated cholesterol levels |
| CA2620274A Active CA2620274C (en) | 2007-02-08 | 2007-08-27 | Methods for the treatment of senile dementia of the alzheimer's type |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2695167A Active CA2695167C (en) | 2007-02-08 | 2007-08-27 | Methods for the treatment of elevated cholesterol levels |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US9034923B2 (enExample) |
| EP (2) | EP2117527B1 (enExample) |
| JP (1) | JP5470050B2 (enExample) |
| AU (1) | AU2007346587C1 (enExample) |
| CA (2) | CA2695167C (enExample) |
| IL (1) | IL200029A0 (enExample) |
| SG (1) | SG173418A1 (enExample) |
| WO (1) | WO2008095275A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2695167C (en) | 2007-02-08 | 2011-11-01 | Phenomenome Discoveries Inc. | Methods for the treatment of elevated cholesterol levels |
| TWI475989B (zh) * | 2008-12-22 | 2015-03-11 | Phenomenome Discoveries Inc | 縮醛磷脂類化合物，含彼之醫藥組成物以及治療老化疾病的方法 |
| EP3124980A1 (en) | 2009-10-01 | 2017-02-01 | Phenomenome Discoveries Inc. | Mass spectrophotometric method to diagnose pancreatic cancer |
| WO2019060298A1 (en) | 2017-09-19 | 2019-03-28 | Neuroenhancement Lab, LLC | METHOD AND APPARATUS FOR NEURO-ACTIVATION |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| WO2019133997A1 (en) | 2017-12-31 | 2019-07-04 | Neuroenhancement Lab, LLC | System and method for neuroenhancement to enhance emotional response |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| WO2020056418A1 (en) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | System and method of improving sleep |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| CN114236019B (zh) * | 2022-02-24 | 2022-05-06 | 宝枫生物科技（北京）有限公司 | 脑白质病变的生物标志物的应用 |
| CN118512461A (zh) * | 2024-06-03 | 2024-08-20 | 东莞市第八人民医院（东莞市儿童医院） | 一种母乳来源磷脂在防治支气管肺发育不良的应用 |
| CN119876292B (zh) * | 2025-03-27 | 2025-06-03 | 浙江省白马湖实验室有限公司 | 一种酰胺类缩醛磷脂化合物的制备方法及应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994009371A1 (en) | 1992-10-09 | 1994-04-28 | Massachusetts Institute Of Technology | Antemortem diagnostic test for alzheimer's disease |
| FR2736265B1 (fr) | 1995-07-07 | 1997-09-26 | Forgeot Marcel | Nouvelles compositions a base de phosphoglycero ethers et leur utilisation dans le traitement des maladies neuro-degeneratives |
| US5731354A (en) | 1996-05-06 | 1998-03-24 | Clarion Pharmaceuticals Inc. | Treatment for the inhibition of neuro-degenerative disease states |
| US6177476B1 (en) | 1998-08-27 | 2001-01-23 | Clarion Pharmaceuticals Inc. | Nutritional supplements for replenishing plasmalogens |
| CA2298181C (en) | 2000-02-02 | 2006-09-19 | Dayan Burke Goodnough | Non-targeted complex sample analysis |
| US20020009740A1 (en) | 2000-04-14 | 2002-01-24 | Rima Kaddurah-Daouk | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| AU2001286059A1 (en) | 2000-09-08 | 2002-03-22 | Oxford Glycosciences (Uk) Ltd. | Automated identification of peptides |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| AU2002338348A1 (en) | 2001-04-06 | 2002-10-21 | Biovision Ag | Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents |
| WO2002090974A2 (de) | 2001-05-09 | 2002-11-14 | Biovision Ag | Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien |
| IL163617A0 (en) | 2002-03-22 | 2005-12-18 | Phenomenome Discoveries Inc | Method of visualizing non-targeted metabolomic data generated from fourier transform ion cyclotron resonance mass spectrometers |
| JP2004026803A (ja) | 2002-03-29 | 2004-01-29 | Nof Corp | 神経細胞死予防剤 |
| CA2745731C (en) | 2002-08-23 | 2015-05-12 | Bayer Schering Pharma Aktiengesellschaft | Biomarkers for diagnosing alzheimer's disease |
| SE0203886D0 (sv) * | 2002-12-27 | 2002-12-27 | Ltp Lipid Technologies Provide | Glycerolesterprodukt och dess användning |
| US20040191294A1 (en) * | 2003-03-27 | 2004-09-30 | Ramaprasad Talahalli Ravichandra | Health composition |
| WO2004093910A1 (ja) | 2003-04-22 | 2004-11-04 | Astellas Pharma Inc. | ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤 |
| EP1694816B1 (en) | 2003-11-07 | 2013-08-28 | Ciphergen Biosystems, Inc. | Biomarkers for alzheimer's disease |
| WO2005085838A2 (en) | 2004-03-02 | 2005-09-15 | Vanderbilt University | Computational analysis of mass spectroscopic lipid data |
| WO2005116659A2 (en) | 2004-05-18 | 2005-12-08 | Neurodx, Llc | Compositions and methods relating to alzheimer’s disease |
| WO2007002285A2 (en) * | 2005-06-21 | 2007-01-04 | The Trustees Of The University Of Pennsylvania | Methods for treating neurological and psychiatric conditions |
| JP4176749B2 (ja) | 2005-07-29 | 2008-11-05 | 学校法人帝京大学 | 疾病検査法 |
| EP1931995A4 (en) | 2005-09-12 | 2010-08-04 | Phenomenome Discoveries Inc | METHODS FOR DIAGNOSING PATHOLOGICAL CONDITIONS DUE TO COLORECTAL CANCER AND OVARIAN CANCER |
| US20090057553A1 (en) | 2005-09-15 | 2009-03-05 | Phenomenome Discoveries Inc. | Method and apparatus for fourier transform ion cyclotron resonance mass spectrometry |
| EP2322531A3 (en) | 2006-02-28 | 2011-09-07 | Phenomenome Discoveries Inc. | Methods for the diagnosis of dementia and other neurological disorders |
| CN101479230A (zh) | 2006-05-26 | 2009-07-08 | 菲诺梅诺米发现公司 | 用于诊断多发性硬化的生物标记及其方法 |
| US20100105635A1 (en) * | 2007-01-30 | 2010-04-29 | Tohoku University | Composition for prevention or treatment of disease associated with amyloidosis through inhibition of amyloid protein aggregation and promotion of amyloid protein degradation |
| CA2695167C (en) | 2007-02-08 | 2011-11-01 | Phenomenome Discoveries Inc. | Methods for the treatment of elevated cholesterol levels |
| US8026099B2 (en) | 2007-07-26 | 2011-09-27 | Washington University | Lipid profile as a biomarker for early detection of neurological disorders |
-
2007
- 2007-08-27 CA CA2695167A patent/CA2695167C/en active Active
- 2007-08-27 CA CA2620274A patent/CA2620274C/en active Active
- 2007-08-27 WO PCT/CA2007/001472 patent/WO2008095275A1/en not_active Ceased
- 2007-08-27 EP EP07800499.1A patent/EP2117527B1/en active Active
- 2007-08-27 AU AU2007346587A patent/AU2007346587C1/en active Active
- 2007-08-27 SG SG2011053717A patent/SG173418A1/en unknown
- 2007-08-27 US US12/090,342 patent/US9034923B2/en active Active
- 2007-08-27 JP JP2009548551A patent/JP5470050B2/ja active Active
- 2007-08-27 EP EP13160192.4A patent/EP2620147B1/en active Active
-
2009
- 2009-07-23 IL IL200029A patent/IL200029A0/en unknown
-
2012
- 2012-06-18 US US13/526,197 patent/US8993623B2/en active Active
-
2015
- 2015-03-19 US US14/663,440 patent/US20160015673A1/en not_active Abandoned
- 2015-03-31 US US14/674,705 patent/US9517222B2/en active Active
-
2016
- 2016-11-11 US US15/349,831 patent/US10123989B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2695167A1 (en) | 2008-06-20 |
| AU2007346587A1 (en) | 2008-08-14 |
| SG173418A1 (en) | 2011-08-29 |
| US9034923B2 (en) | 2015-05-19 |
| JP2010518029A (ja) | 2010-05-27 |
| US20130046016A1 (en) | 2013-02-21 |
| EP2117527B1 (en) | 2020-06-17 |
| US9517222B2 (en) | 2016-12-13 |
| EP2620147A3 (en) | 2013-10-02 |
| US20150306057A1 (en) | 2015-10-29 |
| EP2117527A4 (en) | 2012-09-12 |
| JP5470050B2 (ja) | 2014-04-16 |
| US10123989B2 (en) | 2018-11-13 |
| US20160015673A1 (en) | 2016-01-21 |
| AU2007346587B2 (en) | 2014-03-27 |
| US8993623B2 (en) | 2015-03-31 |
| CA2620274A1 (en) | 2008-06-20 |
| IL200029A0 (en) | 2010-04-15 |
| US20120129934A1 (en) | 2012-05-24 |
| EP2620147B1 (en) | 2020-06-03 |
| US20170056363A1 (en) | 2017-03-02 |
| EP2620147A2 (en) | 2013-07-31 |
| WO2008095275A1 (en) | 2008-08-14 |
| AU2007346587C1 (en) | 2015-01-22 |
| EP2117527A1 (en) | 2009-11-18 |
| CA2695167C (en) | 2011-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2620274C (en) | Methods for the treatment of senile dementia of the alzheimer's type | |
| Corrigan et al. | Abnormal content of n− 6 and n− 3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content | |
| Goodenowe et al. | Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia | |
| US9375408B2 (en) | Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment | |
| Butovich et al. | Delineating a novel metabolic high triglycerides-low waxes syndrome that affects lipid homeostasis in meibomian and sebaceous glands | |
| Bartov et al. | Low molecular weight thiol amides attenuate MAPK activity and protect primary neurons from Aβ (1–42) toxicity | |
| Gregoire et al. | Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys | |
| Song et al. | Effects of dietary glucocerebrosides from sea cucumber on the brain sphingolipid profiles of mouse models of Alzheimer's disease | |
| Lin et al. | Beyond glucose: metabolic shifts in responses to the effects of the oral glucose tolerance test and the high-fructose diet in rats | |
| Yu et al. | Membrane aging as the real culprit of Alzheimer’s disease: modification of a hypothesis | |
| Santoro et al. | L-Carnitine protects mammalian cells from chromosome aberrations but not from inhibition of cell proliferation induced by hydrogen peroxide | |
| Wood et al. | Plasmalogen deficit: a new and testable hypothesis for the etiology of Alzheimer’s disease | |
| AU2014201707B2 (en) | Methods for the treatment of Senile Dementia of the Alzheimer's Type | |
| HK1182935A (en) | Compounds for lowering cholesterol | |
| HK1131348B (en) | Compounds for use in the treatment of senile dementia of the alzheimer's type | |
| HK1131348A (en) | Compounds for use in the treatment of senile dementia of the alzheimer's type | |
| HK1182935B (en) | Compounds for lowering cholesterol | |
| Sibomana et al. | Influence of myo-inositol plus ethanolamine on plasmalogens and cell viability during oxidative stress | |
| EP3209637B1 (en) | 2-hydroxy-triacylglycerol compounds for use in treating disease | |
| JP7161781B2 (ja) | 環状プラスメニルエタノールアミン | |
| MIRINTHORN | Glucosylceramide structure and its oxidative modification affect antiinflammatory activity in the differentiated Caco-2 cells | |
| Saitoh et al. | Changes in the amounts of myelin lipids and molecular species of plasmalogen PE in the brain of an autopsy case with d-bifunctional protein deficiency | |
| Chamulitrat et al. | Critical Role of Hepatic Fatty-Acyl Phospholipid Remodeling in Obese and Nonobese Fatty Liver Mouse Models | |
| Di et al. | A platform for the analysis of metabolites in endocannabinoids-related pathways. | |
| Tian | Discovery of Novel Acrolein Scavengers and Their Neuroprotective Effects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |